Welcome to our dedicated page for Fonar news (Ticker: FONR), a resource for investors and traders seeking the latest updates and insights on Fonar stock.
Fonar Corporation (NASDAQ: FONR) is a medical device manufacturer and diagnostic imaging services company focused on magnetic resonance imaging (MRI). Company news releases highlight its role as "The Inventor of MR Scanning™" and describe how it designs, manufactures, sells and services MRI scanners while also managing MRI centers through its wholly owned subsidiary Health Management Company of America (HMCA). This news page aggregates announcements that relate directly to Fonar’s operations, technology and corporate actions.
Readers can find detailed coverage of Fonar’s periodic financial results, including quarterly and annual updates that discuss total revenues, income from operations, net income, cash and cash equivalents, working capital and scan volumes at HMCA-managed MRI centers. These releases often explain trends in MRI scan volume, the number of scanners managed in New York and Florida, and the impact of adding new scanners or centers to Fonar’s network.
Fonar’s news also frequently addresses developments in its MRI technology and service offerings. The company regularly describes the performance and use of its FONAR UPRIGHT® Multi-Position™ MRI (STAND-UP® MRI), which can scan patients in weight-bearing positions and is presented as a patient-friendly alternative to conventional lie-down scanners. Updates may include information on new high-field MRI installations at HMCA-managed centers and how combinations of STAND-UP® MRI and high-field systems affect scheduling and referral patterns.
Corporate governance and transaction-related announcements form another important part of Fonar’s news flow. In 2025 the company reported the receipt of non-binding and supplemental proposals from an acquisition group led by its chief executive officer to take the company private, followed by a definitive merger agreement providing for an all-cash acquisition of shares not owned by the group. News releases also cover board changes, such as director retirements and the appointment of an independent director with public accounting experience.
For investors and observers tracking FONR, this news stream provides primary-source information about Fonar’s financial performance, MRI center operations, product positioning, patent-related developments and the progress of its proposed going-private transaction. Regular updates help contextualize how the company’s MRI technology, HMCA-managed networks and capital markets activity evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FONAR (NASDAQ: FONR) reported Q2 fiscal 2026 results for the quarter ended December 31, 2025. Total revenue was $25.5M (up 2% YoY) and six-month revenue was $51.6M (up 3% YoY). Quarterly net income rose 15% to $2.5M; diluted EPS was $0.31.
Operating cash flow for the six months fell 52% to $1.9M. On December 29, 2025, the company signed a definitive merger agreement that raised the proposed take-private cash price to $19.00 per share.
FONAR (NASDAQ: FONR) entered a definitive agreement on December 23, 2025 for an all-cash take-private sale to an acquisition group led by CEO Timothy Damadian. Under the Merger Agreement, holders of common stock will receive $19.00 per share at closing; other classes receive $19.00 (Class B), $6.34 (Class C) and $10.50 (Class A non-voting preferred). The $19.00 common share price represents a 31.5% premium to the last close before the announcement and a 39.7% premium to the 90-day average ending June 30, 2025.
The deal is expected to close in Q3 2026, is not subject to financing conditions, requires stockholder approval and will result in delisting from Nasdaq upon closing. Financing includes a $35M debt commitment from OceanFirst Bank plus approximately $10M additional debt and $45M equity from the acquisition group and third parties.
FONAR (NASDAQ: FONR) reported 1Q fiscal 2026 results for the quarter ended September 30, 2025. Total revenues rose 4% to $26.0M, driven by the HMCA diagnostic-imaging segment at $23.5M and FONAR product/services at $2.5M (+14%).
Operating income fell 30% to $3.2M, consolidated net income fell 33% to $2.7M, and diluted EPS declined 26% to $0.34. SG&A increased 33% to $6.8M. Cash and short-term investments were $54.3M at September 30, 2025. HMCA reported scan volume of 55,106 (3.9% YoY growth).
FONAR Corporation (NASDAQ: FONR), a pioneer in MRI technology, reported mixed financial results for fiscal 2025. Total revenues increased 1% to $104.4 million, while net income decreased 24% to $10.7 million. The company's diagnostic imaging subsidiary, HMCA, achieved record scan volume of 216,317 scans, up 3.3% from the previous year.
Key financial metrics include diluted EPS of $1.23 (down 20%), cash and equivalents of $56.3 million, and working capital growth of 4% to $127.5 million. HMCA expanded its operations by adding two MRI scanners, bringing the total to 44 managed scanners across New York and Florida. The company's stock repurchase plan has acquired 373,942 shares for $6.07 million but is temporarily suspended due to a potential "Take Private" transaction.
FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning, has received a supplemental "take private" proposal from a group led by Timothy Damadian. The Proposed Acquisition Group aims to acquire all outstanding shares not currently owned by them at $17.25 per share in cash.
The offer represents a 27% premium over the 90-day average closing price ending June 30, 2025. This follows an initial expression of interest from July 7, 2025. A Special Committee of independent directors will review the proposal with financial and legal advisors to determine the best course of action for FONAR and its shareholders.
The company emphasizes that this is only a preliminary proposal and no decisions have been made. No shareholder action is required at this time.